No Data
US Stock MarketDetailed Quotes
IQV IQVIA Holdings
Watchlist
213.810
+2.810+1.33% Close 11/29 16:00 ET
213.8100.0000.00%
Post 16:02 ET
216.245High212.000Low1.20MVolume
212.780Open211.000Pre Close258.44MTurnover0.67%Turnover Ratio35.87P/E (TTM)39.02BMarket Cap241.86052wk High37.38P/E (Static)182.50MShares167.42052wk Low6.72P/B38.70BFloat Cap285.610Historical High--Dividend TTM181.00MShs Float81.790Historical Low--Div YieldTTM2.01%Amplitude214.563Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About IQVIA Holdings Company
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Revenue Breakdown
Business
Unit:USD
2022/12/31
Stock NameRevenueRatio
Research & Development Solutions7.92B54.97%
Technology & Analytics Solutions5.75B39.88%
Contract Sales & Medical Solutions743M5.16%
News
Price Over Earnings Overview: IQVIA Hldgs
Looking into the current session, IQVIA Hldgs Inc. (NYSE:IQV) shares are trading at $212.73, after a 0.95% spike. Moreover, over the past month, the stock went up by 17.57%, but in the past year, fell
What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Biogen (BIIB)
Comments
Bio-Rad Laboratories is likely to maintain an 80% market share in digital PCR products due to extensive offering and embracing continuous investment. Bio-Techne's extensive product offerings and the growth of its analytical instruments business are likely to drive its growth. For IQVIA, sales growth is primarily expected from managing its existing backlog.
Bio-Rad, IQVIA, Bio-Techne Among Top Picks at Credit Suisse
ColumnsWhat to Expect in the Week Ahead (Powell Speaks; DIS, PYPL and UBER Earnings)
Fourth-quarter earnings season continues this week, with close to 90 $S&P 500 Index(.SPX.US$ companies scheduled to report. So far, earnings are down about 3% from the same period a year ago, per Refinitiv.
$Simon Property(SPG.US$, $Take-Two Interactive Software(TTWO.US$, and $Tyson Foods(TSN.US$ report on Monday, followed by $BP PLC(BP.US$, $DuPont(DD.US$, and $Royal Caribbean(RCL.US$.
$Disney(DIS.US$, $CVS Health(CVS.US$, and ...
$Simon Property(SPG.US$, $Take-Two Interactive Software(TTWO.US$, and $Tyson Foods(TSN.US$ report on Monday, followed by $BP PLC(BP.US$, $DuPont(DD.US$, and $Royal Caribbean(RCL.US$.
$Disney(DIS.US$, $CVS Health(CVS.US$, and ...
+3
18
3
ColumnsUS Top Rating Updates on 11/17: TGT, EL, ICE, IQV and More
Target Upgraded to Overweight From Neutral at Piper Sandler
Piper Sandler analyst Edward Yruma upgraded $Target(TGT.US$ to Overweight from Neutral with a price target of $200, up from $190. The company has had a difficult 2022, but we are approaching "trough" EBIT margins and the stock's valuation now "looks compelling," Yruma tells investors in a research note.
Canaccord Starts Estee Lauder With Hold, Sees Estimate Risk
Canaccord analys...
Piper Sandler analyst Edward Yruma upgraded $Target(TGT.US$ to Overweight from Neutral with a price target of $200, up from $190. The company has had a difficult 2022, but we are approaching "trough" EBIT margins and the stock's valuation now "looks compelling," Yruma tells investors in a research note.
Canaccord Starts Estee Lauder With Hold, Sees Estimate Risk
Canaccord analys...
11
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--